Mustang Bio, Inc. (MBIO) 株式分析

企業概要

Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical enterprise dedicated to translating advanced cell therapies into potential cures for patients suffering from difficult-to-treat cancers and autoimmune diseases within the United States. The company operates within the healthcare sector, specifically the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities rather than established product sales. As of the latest reporting period, the company possesses a market capitalization of $5.63M and employs approximately 4 individuals, reflecting a very small-scale operation typical of early-stage biotech ventures. These financial metrics indicate that Mustang Bio is a micro-cap entity with minimal annual revenue recorded, positioning it as a speculative investment where value is derived entirely from future potential rather than current cash flows or profitable operations. The negligible employee count relative to the sector suggests a lean organizational structure, likely relying on external partnerships or a highly specialized team to advance its pipeline, which currently centers on the development of MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy in Phase I trials.

財務健全性

The company's financial statements show a Net Income (TTM) of $-1,921,000 and an EBITDA of $-2,398,000, while Revenue (TTM) is listed as N/A, indicating that the firm has not yet generated significant commercial sales. The substantial gap between the reported revenue and the negative net income highlights an aggressive cost structure where operating expenses significantly outweigh any current income, a common characteristic in the pre-commercialization phase of biotechnology. Free Cash Flow stands at $-4,149,000, which signifies that the company is burning through its cash reserves to fund its research and development pipeline, thereby limiting its immediate financial flexibility and reliance on external capital markets. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability or scale to generate positive margins on its activities. On the balance sheet, the company holds $17.27M in cash against $0 in debt, resulting in a Debt to Equity ratio of N/A, which portrays a highly conservative capital structure devoid of leverage. The Current Ratio is 2.22, suggesting that the company maintains sufficient liquid assets to cover its short-term liabilities with a comfortable margin of safety. Return on Equity is -67.9% and Return on Assets is -11.3%, revealing that management's current effectiveness in generating returns is negative, as the company is consuming equity and assets to build its pipeline rather than generating yield.

バリュエーション評価

The Trailing P/E Ratio (TTM) is N/A due to the absence of net income, while the Forward P/E is calculated at -2.12, implying that the market is pricing in future earnings expectations that are currently negative or unprofitable. The Price to Book ratio is 0.57, which indicates that the market is valuing the company at a significant discount to its book value, a typical valuation characteristic for speculative biotechnology firms with limited tangible assets relative to their intellectual property. The Price to Sales ratio is N/A and the EV/EBITDA stands at 4.85, suggesting that traditional sales-based valuation models are not applicable, and the multiple is driven more by enterprise value considerations relative to negative earnings. The 52-Week High is $7.00 and the 52-Week Low is $0.53, meaning the current trading price sits somewhere within this wide range, reflecting high volatility and significant uncertainty regarding the stock's immediate price direction. The Beta value is 2.18, which indicates that the stock price is expected to be 2.18 times more volatile than the broader market, exposing investors to substantial risk during periods of market turbulence.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the fact that the company has not yet established a recurring revenue base or consistent earnings history to calculate growth rates. Consequently, there is no dividend yield or payout ratio available, as the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all its earnings to reinvest into its clinical development rather than distributing income to shareholders. Since the company does not pay dividends, its growth strategy relies entirely on the successful advancement of its clinical pipeline and the eventual commercialization of its therapies, rather than returning capital to investors through cash distributions. The overall growth and income profile is characterized by a lack of current income generation and undefined historical growth rates, focusing exclusively on the long-term potential of its biotechnology assets and the successful completion of its Phase I trials.